Alan N. Engelman is a Professor in the Department of Medicine at Harvard Medical School and in the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute in Boston, Massachusetts. His research primarily focuses on the mechanism of retroviral DNA integration. Integration is critical to retroviral replication and the responsible viral enzyme, integrase, is a key drug target in the treatment of HIV,AIDS. Dr. Engelman’s research contributed to the understanding of the mechanism of action of the clinical integrase strand transfer inhibitors, which are a favored component in front line therapy. His research has additionally yielded significant insight into the mechanism of action of a second type of HIV-1 inhibitor, the allosteric integrase inhibitors, that inhibit virus particle maturation, as well as the structural basis of retroviral DNA integration.